Mishra Yachana, Chattaraj Aditi, Mishra Vijay, Ranjan Abhigyan, Tambuwala Murtaza M
School of Bioengineering and Biosciences, Lovely Professional University, Phagwara 144411, Punjab, India.
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411, Punjab, India.
Pharmaceuticals (Basel). 2023 Jun 6;16(6):849. doi: 10.3390/ph16060849.
Cancer is one of the diseases that causes a high mortality as it involves unregulated and abnormal cell growth proliferation that can manifest in any body region. One of the typical ovarian cancer symptoms is damage to the female reproductive system. The death rate can be reduced through early detection of the ovarian cancer. Promising probes that can detect ovarian cancer are suitable aptamers. Aptamers, i.e., so-called chemical antibodies, have a strong affinity for the target biomarker and can typically be identified starting from a random library of oligonucleotides. Compared with other probes, ovarian cancer targeting using aptamers has demonstrated superior detection effectiveness. Various aptamers have been selected to detect the ovarian tumor biomarker, vascular endothelial growth factor (VEGF). The present review highlights the development of particular aptamers that target VEGF and detect ovarian cancer at its earliest stages. The therapeutic efficacy of aptamers in ovarian cancer treatment is also discussed.
癌症是导致高死亡率的疾病之一，因为它涉及不受调控的异常细胞生长增殖，可出现在身体的任何部位。典型的卵巢癌症状之一是女性生殖系统受损。通过早期检测卵巢癌可降低死亡率。有前景的可检测卵巢癌的探针是合适的适配体。适配体，即所谓的化学抗体，对目标生物标志物具有很强的亲和力，通常可从随机寡核苷酸文库开始鉴定。与其他探针相比，使用适配体靶向检测卵巢癌已显示出卓越的检测效果。已筛选出多种适配体来检测卵巢肿瘤生物标志物血管内皮生长因子（VEGF）。本综述重点介绍了靶向VEGF并在卵巢癌最早阶段进行检测的特定适配体的研发情况。还讨论了适配体在卵巢癌治疗中的疗效。
